ASX:IMU Imugene (IMU) Stock Price, News & Analysis → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Free IMU Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume12.70 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.03%Price TargetN/A Stock AnalysisStock Analysis Get Imugene alerts: Email Address Ad InvestorPlaceNew crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About Imugene Stock (ASX:IMU)Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.Read More Ad InvestorPlaceNew crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. IMU Stock News HeadlinesApril 17, 2024 | bizjournals.comCell therapy firm acquires RTP manufacturing facilityApril 16, 2024 | finance.yahoo.comImugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 millionApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 15, 2024 | markets.businessinsider.comBile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohortApril 15, 2024 | finance.yahoo.comBile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohortApril 15, 2024 | finance.yahoo.comImugene opens enrolment for Bile Tract Cancer expansion studyApril 15, 2024 | msn.comASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer’sApril 10, 2024 | finance.yahoo.comCity of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual MeetingApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 9, 2024 | finanznachrichten.deImugene Limited: Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024April 9, 2024 | finance.yahoo.comImugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024April 3, 2024 | msn.comGuess which ASX 300 healthcare stock is storming higher on Chinese patent newsMarch 27, 2024 | finance.yahoo.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business UpdateMarch 15, 2024 | finance.yahoo.comU.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for EnsartinibMarch 14, 2024 | finance.yahoo.comPendulum Therapeutics Introduces GLP-1 ProbioticMarch 13, 2024 | finance.yahoo.comUnityPoint in Des Moines releases renderings for mental health expansionMarch 13, 2024 | finance.yahoo.comNovartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune SystemMarch 12, 2024 | finance.yahoo.comapoQlar enters into Collaboration with Mayo Clinic to Advance Patient Care with Extended Reality TechnologyMarch 11, 2024 | finanznachrichten.deImugene Limited: Phase 1 onCARlytics solid tumour trial advances to combination arm treatmentMarch 11, 2024 | au.investing.comFIVE at FIVE AU: Biggest fall on ASX in eight monthsMarch 11, 2024 | au.investing.comImugene advances to combination dosing with Phase 1 onCARlytics solid tumour trialMarch 10, 2024 | afr.comBarrenjoey, Canaccord raising for Lake Resources; 39.1pc discountFebruary 22, 2024 | finance.yahoo.comImugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology CatalystsFebruary 20, 2024 | msn.com4 things a doctor who's written best-selling books about aging does daily in the hope of living longerFebruary 15, 2024 | proactiveinvestors.comImugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trialFebruary 3, 2024 | msn.comBritish Punjabi doctor leads ground-breaking international trial of bowel cancer vaccineJanuary 23, 2024 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsSee More Headlines Receive IMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2019Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:IMU CUSIPN/A CIKN/A Webwww.imugene.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.37% Return on Assets-26.15% Debt Debt-to-Equity Ratio3.33 Current Ratio5.73 Quick Ratio15.17 Sales & Book Value Annual Sales$15.03 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.75 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares7,390,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta3.23 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)B.A (UNSW), FAICD, Executive Chairman Comp: $316.1kMs. Leslie ChongCEO, MD & Executive DirectorMr. Michael Tonroe ACA (Age 58)B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD, CFO & Company Secretary Comp: $424.28kDr. Nicholas J. Ede B.Sc.(Hons.)Ph.D., Head of Corporate DevelopmentDr. Monil Shah M.B.A.Pharm.D., Chief Business OfficerDr. Bradley Glover Ph.D. (Age 55)Chief Operating Officer Ms. Ursula McCurrySenior Vice President of Clinical OperationsDr. John ByonSenior Vice President of Clinical DevelopmentDr. Joseph Paul Woodard Jr.M.D., Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPaul HopperSold 1,381,422 sharesTotal: $20,721.33 ($0.02/share)Lesley RussellSold 1,000,000 sharesTotal: $120,000.00 ($0.12/share)Paul HopperSold 535,714 sharesTotal: $24,107.13 ($0.05/share)Jens EcksteinSold 238,095 sharesTotal: $19,999.98 ($0.08/share) IMU Stock Analysis - Frequently Asked Questions How were Imugene's earnings last quarter? Imugene Limited (ASX:IMU) posted its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter. What other stocks do shareholders of Imugene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Imugene investors own include Leap Therapeutics (LPTX), LightPath Technologies (LPTH), Jaguar Health (JAGX), Groupon (GRPN), Greenland Minerals (GGG), Fortescue (FMG), Diffusion Pharmaceuticals (DFFN), Alumina (AWC) and Atossa Therapeutics (ATOS). This page (ASX:IMU) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.